@article {Hu2021.09.02.21263010, author = {Zhiliang Hu and Bilin Tao and Zhongqi Li and Yan Song and Changhua Yi and Junwei Li and Meng Zhu and Yongxiang Yi and Peng Huang and Jianming Wang}, title = {Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China}, elocation-id = {2021.09.02.21263010}, year = {2021}, doi = {10.1101/2021.09.02.21263010}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The SARS-CoV-2 B.1.617.2 (Delta) variant has caused a new surge in the number of COVID-19 cases. The effectiveness of vaccines against this variant is not fully understood. Using data from a recent large-scale outbreak of COVID-19 in China, we conducted a real-world study to explore the effect of inactivated vaccine immunization on the course of disease in patients infected with Delta variants. We recruited 476 confirmed cases over the age of 18, of which 42 were severe. After adjusting for age, gender, and comorbidities, patients who received two doses of inactivated vaccine (fully vaccinated) had an 88\% reduced risk in progressing to the severe stage (adjusted OR: 0.12, 95\% CI: 0.02- 0.45). However, this protective effect was not observed in patients who only received only one dose of the vaccine(adjusted OR: 1.11, 95\% CI: 0.51- 2.36). The full immunization offered 100\% protection from a severe illness among women. The effect of the vaccine was potentially affected by underlying medical conditions (OR: 0.26, 95\% CI: 0.03-1.23). This is the largest real-world study confirming the effectiveness of inactive COVID-19 vaccines against severe illness in Delta variant-infected patients in Jiangsu, China.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Key Research and Development Program of Department of Health of Jiangsu (ZDB2020036), and Project of Nanjing Infectious Disease Clinical Medical Center Construction (NA2021062071). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of Nanjing Public Health Medical Center. Written informed consent was waived by the Ethics Commission.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSome or all data, models, or code that support the findings of this study are available from the corresponding author upon reasonable request.}, URL = {https://www.medrxiv.org/content/early/2021/09/05/2021.09.02.21263010}, eprint = {https://www.medrxiv.org/content/early/2021/09/05/2021.09.02.21263010.full.pdf}, journal = {medRxiv} }